News Sentiment

PASG sentiment intelligence

Passage Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.57 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

72/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.4% over one week, -21.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 72/100 classification
One-week reaction -2.4% Price reacting lower
Trend fit Trend inactive -21.3% over four weeks
Fair value -65.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 29
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Stock Titan 8
Market source 6
AD HOC NEWS 2
The Business Journals 2
Moomoo 2
MT Newswires 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 17
Deals and strategy 17
Earnings 13
Regulatory and legal 2
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
TradingKey Direct company coverage

Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Passage Bio Inc (PASG), detailing analyst ratings, price targets, and EPS expectations. Based on 4 analysts, the current rating is "Hold" with a target price of USD 53.50, suggesting a significant upside. The report highlights past E

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:10
Source
TradingKey
TradingKey Direct company coverage

Passage Bio Inc (PASG) Institutional Confidence

This article provides details on Passage Bio Inc (PASG) stock, focusing on its institutional confidence and shareholder activity. It lists key institutional holders, their share counts, and recent changes in their holdings, such as increases by Renaissance Technologies LLC and Ge

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:10
Source
TradingKey
Moomoo Direct company coverage

Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating

Guggenheim has downgraded Passage Bio (PASG.US) from a "Buy" rating to a "Hold" rating. This change reflects a revised outlook from the investment firm regarding the company's stock performance.

Tone
Negative 29/100
Event
Guidance
Published
10 Jun 2026 17:40
Source
Moomoo
GuruFocus Direct company coverage

Passage Bio (PASG) Downgraded to Neutral as Strategic Review Initiated

Guggenheim analyst Debjit Chattopadhyay has downgraded Passage Bio (PASG) from "Buy" to "Neutral" and ceased coverage, citing uncertainties as the company begins a strategic review to enhance shareholder value, potentially through mergers or acquisitions. Passage Bio, a biotechno

Tone
Negative 29/100
Event
Deals and strategy
Published
10 Jun 2026 12:10
Source
GuruFocus
Zacks Investment Research Direct company coverage

Should I buy Passage Bio (PASG)

Tone
Positive 66/100
Event
Market update
Published
15 Aug 2025 07:00
Source
Zacks Investment Research